Helus Pharma Inc Ordinary Shares R7E0
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- €9.24
- Day Range
- €10.22–10.22
- 52-Week Range
- €9.17–10.22
- Bid/Ask
- €0.00 / €0.00
- Shares Outstanding
- 73.07M
- Market Cap
- €746.77M
- Volume/Avg
- — / —
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Helus Pharma Inc, the commercial operating name of Cybin Inc, is a clinical-stage pharmaceutical company focused on developing proprietary neuroactive compounds, referred to as NSAs, which are synthetic molecules designed to target serotonin pathways. The company's programs are aimed at treating mental health conditions such as depression and anxiety. Its pipeline includes HLP003, which is in clinical development for the adjunctive treatment of depressive disorder, and HLP004, which is in clinical development for generalized anxiety disorder. The company also conducts research on additional investigational compounds.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Growth
- Total Number of Employees
- 50
- Website
- https://www.helus.com
Valuation
|
Metric
|
R7E0
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 4.22 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
R7E0
|
|---|---|
Quick Ratio | 9.76 |
Current Ratio | 10.97 |
Interest Coverage | — |
Quick Ratio
R7E0
Profitability
|
Metric
|
R7E0
|
|---|---|
Return on Assets (Normalized) | −62.05% |
Return on Equity (Normalized) | −108.77% |
Return on Invested Capital (Normalized) | −69.01% |
Return on Assets
R7E0
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|r!QPv>^ | LOCK|wZ$<L | $129B | |||
| Moderna Inc
MRNA
| LOCK|^^?@?nH | LOCK|v^^ | $85B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|Z&SR>W$ | LOCK|%TG?N | $79B | |||
| argenx SE ADR
ARGX
| LOCK|>>T>fr | LOCK|X! | $52B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|FK!%qV | LOCK|%@ | $41B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|##NsynK | LOCK|K@bW | $30B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|w#bxKVmN | LOCK|GB^By | $26B | |||
| BioNTech SE ADR
BNTX
| LOCK|wzl$dl | LOCK|$^N | $24B | |||
| Incyte Corp
INCY
| LOCK|TR$KM< | LOCK|L?n | $23B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| LOCK|SY&g?z@ | LOCK|pMr | $14B |
United States